PR Newswire
MILWAUKEE, Dec. 22, 2023
MILWAUKEE, Dec. 22, 2023 /PRNewswire/ -- Ademi LLP is investigating Theseus (NASDAQ: THRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra.
Click here to learn how to join the https://www.ademilaw.com/case/theseus-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
In the transaction, Theseus stockholders will receive only between $3.90 and $4.05 in cash, consisting of (i) a base cash price of $3.90 per share and (ii) an additional cash amount of not more than $0.15 per share at the closing of the merger, plus one non-tradeable contingent value right representing the right to receive 80% of the net proceeds from any license or disposition of Theseus' programs effected within 180 days of closing of the merger and 50% of the potential aggregate value of certain specified potential cost savings realized within 180 days of the close of the merger.
The transaction agreement unreasonably limits competing transactions for Theseus by imposing a significant penalty if Theseus accepts a competing bid. Theseus insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of Theseus' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own Theseus common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/theseus-pharmaceuticals-inc.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-theseus-pharmaceuticals-inc-has-obtained-a-fair-price-in-its-transaction-with-concentra-302021776.html
SOURCE Ademi LLP
